Aichi - Research on Combination therapy in Hypertension (ARCH): Multi-center observational study on hypertensive's actual condition and effectiveness of the patient preference on an ARB and diuretic combination therapy in hypertensive patients who are under drug treatment

Aichi - Research on Combination therapy in Hypertension (ARCH): Multi-center observational study on hypertensive's actual condition and effectiveness of the patient preference on an ARB and diuretic combination therapy in hypertensive patients who are under drug treatment - Aichi - Research on Combination therapy in Hypertension(Arch)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000816

Enrollment

1000

Registered

2007-09-03

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: giving written informed consent. The inclusion criteria for study patients 1.Patients with essential hypertension, who have been previously treated with ARB monotherapy.(Losartan 50 mg, candesartan 8 mg, valsartan 80 mg, telmisartan 40 mg, or olmesartan 20 mg) or combination of ARB and calcium channel blocker (amlodipine 5mg) for more than a month and whose blood pressure has not been adequately controlled with the treatment (SBP >140 mmHg and/or DBP >90mmHg:In the case of a diabetic, SBP >130 mmHg and/or DBP >80mmHg). 2.Patients aged 20 to 80 years at the time of the first visit. 3.Gender is not restricted. 4.Out patients 5.Patients who are able to understand study procedures and agree to participate in the study by

Exclusion criteria

Exclusion criteria: Exclusion criteria 1. Patients with the secondary hypertension 2. Patients with cardiac insufficiency (above NYHA grade III) 3.Women who are pregnant (positive urine pregnancy test at prestudy) or breast feeding, or expecting to conceive duration the study period 4. Patients with a critical liver damage 5. Patient with a history of severe hepatic or renal disease (sCr>2.0mg/dl) 6. Patients with a history of hypersensitivity to ingredients of Preminent. 7. Patients with a history of hypersensitivity to components of thiazide or similar compounds. 8. Patients who are considered to be not eligible to the study by the investigator due to medical reasons.

Design outcomes

Secondary

Measure	Time frame
1.The rate of achieving the target SBP-DBP in three-month treatment 2.DBP change in the three-month treatment 3.The SBP/DBP changes and the rates of achieving the target blood pressure at 3,6, and 12 months 4.The rate of continued treatment and the compliance of the treatment 5.Rates of adverse experiences 6.Subanalysis on patient characteristics between the groups which achieves target blood pressure and which des not	—

Measure

Time frame

1.The rate of achieving the target SBP-DBP in three-month treatment 2.DBP change in the three-month treatment 3.The SBP/DBP changes and the rates of achieving the target blood pressure at 3,6, and 12 months 4.The rate of continued treatment and the compliance of the treatment 5.Rates of adverse experiences 6.Subanalysis on patient characteristics between the groups which achieves target blood pressure and which des not

—

Primary

Measure	Time frame
Systolic-blood-pressure change in three-month treatment.	—

Countries

Japan

Contacts

Public ContactKengo Maeda

Nagoya University Graduate School of Medicine Department of Cardiology

Outcome results